Nanoflavopiridol - JYANT TechnologiesAlternative Names: nanoalvocidib - JYANT Technologies
Latest Information Update: 12 Aug 2016
At a glance
- Originator JYANT Technologies
- Class Antineoplastics; Flavonoids; Piperidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Prostate cancer
Most Recent Events
- 12 Aug 2016 Early research in Prostate cancer (Hormone refractory) in USA (unspecified route)